By Scientia Professor Vlado Perkovic

Journal articles

Wong MG; Lv J; Neuen B; Monaghan H; Billot L; Perkovic V; Zhang H; Kim D, 2024, 'WCN24-1001 EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY', Kidney International Reports, 9, pp. S151 - S151, http://dx.doi.org/10.1016/j.ekir.2024.02.310

Perkovic V; Kollins D; Renfurm R; Papachristofi O; Jacinto-Sanders S; Merkel T; Hach T; Rizk DV, 2024, 'WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 9, pp. S506 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1414

Trimarchi H; Barratt J; Radhakrishnan J; Rizk DV; Sorensen B; Leiske J; Khawaja Z; Campbell K; Perkovic V, 2024, 'WCN24-1837 BEYOND: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ZIGAKIBART IN ADULTS WITH IGA NEPHROPATHY', Kidney International Reports, 9, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.02.362

Barratt J; Rovin B; Murphy E; Komers R; Trimarchi H; Perkovic V, 2024, 'WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL', Kidney International Reports, 9, pp. S505 - S506, http://dx.doi.org/10.1016/j.ekir.2024.02.1413

Heerspink HJL; Jongs N; Schloemer P; Little DJ; Brinker M; Tasto C; Karpefors M; Wheeler DC; Bakris G; Perkovic V; Nkulikiyinka R; Rossert J; Gasparyan SB, 2023, 'Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression', Journal of the American Society of Nephrology, 34, pp. 2025 - 2038, http://dx.doi.org/10.1681/ASN.0000000000000243

Fletcher RA; Jongs N; Chertow GM; McMurray JJV; Arnott C; Jardine MJ; Mahaffey KW; Perkovic V; Rockenschaub P; Rossing P; Correa-Rotter R; Toto RD; Vaduganathan M; Wheeler DC; Heerspink HJL; Neuen BL, 2023, 'Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials', Journal of the American Society of Nephrology, 34, pp. 1965 - 1975, http://dx.doi.org/10.1681/ASN.0000000000000248

Yu J; Sweeting AN; Gianacas C; Houston L; Lee V; Fletcher RA; Perkovic V; Li Q; Neuen BL; Berwanger O; Heerspink HJL; de Zeeuw D; Arnott C, 2023, 'The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 3724 - 3735, http://dx.doi.org/10.1111/dom.15267

Marx N; Deanfield JE; Gerward S; Hovingh GK; Plunde O; Pratley RE; Staerk-Ostergaard J; Perkovic V, 2023, 'Prevalence of systemic inflammation in individuals with atherosclerotic cardiovascular disease: baseline characteristics from the SELECT, SOUL and FLOW phase 3 trials of semaglutide', European Heart Journal, 44, http://dx.doi.org/10.1093/eurheartj/ehad655.2751

Neuen BL; Perkovic V; Bakris GL; Lambers Heerspink H; Vaduganathan M, 2023, 'Abstract 17437: Estimated Lifetime Benefits of Combination Therapy With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-Steroidal MRAs in Patients With Type 2 Diabetes and Albuminuria', Circulation, 148, http://dx.doi.org/10.1161/circ.148.suppl_1.17437

Heerspink HJL; Vart P; Jongs N; Neuen BL; Bakris G; Claggett B; Vaduganathan M; McCausland F; Docherty KF; Jhund PS; Solomon SD; Perkovic V; McMurray JJV, 2023, 'Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials', Diabetes, Obesity and Metabolism, 25, pp. 3327 - 3336, http://dx.doi.org/10.1111/dom.15232

Rossing P; Baeres FMM; Bakris G; Bosch-Traberg H; Gislum M; Gough SCL; Idorn T; Lawson J; Mahaffey KW; Mann JFE; Mersebach H; Perkovic V; Tuttle K; Pratley R, 2023, 'The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease', Nephrology Dialysis Transplantation, 38, pp. 2041 - 2051, http://dx.doi.org/10.1093/ndt/gfad009

Januzzi JL; Mohebi R; Liu Y; Sattar N; Heerspink HJL; Tefera E; Vaduganathan M; Butler J; Yavin Y; Li J; Pollock CA; Perkovic V; Neal B; Hansen MK, 2023, 'Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial', Circulation, 148, pp. 651 - 660, http://dx.doi.org/10.1161/CIRCULATIONAHA.123.065251

Singh AK; Mccausland FR; Claggett BL; Wanner C; Wiecek A; Atkins MB; Carroll K; Perkovic V; Mcmurray JJV; Wittes J; Snapinn S; Blackorby A; Meadowcroft A; Barker T; Dimino T; Mallett S; Cobitz AR; Solomon SD, 2023, 'Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials', Nephrology Dialysis Transplantation, 38, pp. 1890 - 1897, http://dx.doi.org/10.1093/ndt/gfac342

Sridhar VS; Neuen BL; Fletcher RA; Slee A; Ang FG; Rapattoni W; Arnott C; Cherney DZ; Perkovic V; Wheeler DC; Levin A, 2023, 'Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials', Diabetes, Obesity and Metabolism, 25, pp. 2331 - 2339, http://dx.doi.org/10.1111/dom.15112

Kang A; Smyth B; Neuen BL; Heerspink HJL; Di Tanna GL; Zhang H; Arnott C; Hockham C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Mahaffey KW; Perkovic V; Jardine MJ, 2023, 'The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials', Diabetes, Obesity and Metabolism, 25, pp. 2151 - 2162, http://dx.doi.org/10.1111/dom.15091

Fletcher RA; Arnott C; Rockenschaub P; Schutte AE; Carpenter L; Vaduganathan M; Agarwal R; Bakris G; Chang TI; Heerspink HJL; Jardine MJ; Mahaffey KW; Neal B; Pollock C; Jun M; Rodgers A; Perkovic V; Neuen BL, 2023, 'Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials', Journal of the American Heart Association, 12, pp. e028516, http://dx.doi.org/10.1161/JAHA.122.028516

Inker LA; Collier W; Greene T; Miao S; Chaudhari J; Appel GB; Badve SV; Caravaca-Fontán F; Del Vecchio L; Floege J; Goicoechea M; Haaland B; Herrington WG; Imai E; Jafar TH; Lewis JB; Li PKT; Maes BD; Neuen BL; Perrone RD; Remuzzi G; Schena FP; Wanner C; Wetzels JFM; Woodward M; Heerspink HJL; Estacio RO; Hanratty R; Chalmers J; Canetta P; Barrett B; Neal B; Perkovic V; Mahaffey KW; Johnson D; Jardine M; von Eynatten M; Verde E; Verdalles U; Arroyo D; Chapman A; Torres V; Yu A; Brosnahan G; Hannedouche T; Chow KM; Szeto CC; Leung CB; Xie D; Hou FF; Dwyer J; Pohl MA; Raz I; Hunsicker LG; Vanacker A; Malfait T; Maschio G; Locatelli F; Blankestijn PJ; van Zuilen A; Kobayashi F; Makino H; Chan JCN; Andrulli S; Pozzi C; Casartelli D; Praga M; Trujillo H; Cavero T; Sevillano A; Ruggenenti P; Perna A; Carrara F; Keane WF; Manno C; Haynes R; Baigent C; Landray M; Rauen T; Seikrit C; Wied S; Toto RD; de Jong PE; Saddelli M, 2023, 'A meta-analysis of GFR slope as a surrogate endpoint for kidney failure', Nature Medicine, 29, pp. 1867 - 1876, http://dx.doi.org/10.1038/s41591-023-02418-0

Yi TW; Wong MMY; Neuen BL; Arnott C; Poirier P; Seufert J; Slee A; Rapattoni W; Ang FG; Wheeler DC; Mahaffey KW; Perkovic V; Levin A, 2023, 'Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 2043 - 2047, http://dx.doi.org/10.1111/dom.15065

Heerspink HJL; Jongs N; Neuen BL; Schloemer P; Vaduganathan M; Inker LA; Fletcher RA; Wheeler DC; Bakris G; Greene T; Chertow GM; Perkovic V, 2023, 'Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials', Kidney International, 104, pp. 181 - 188, http://dx.doi.org/10.1016/j.kint.2023.03.037

Yi TW; Smyth B; Di Tanna GL; Arnott C; Cardoza K; Kang A; Pollock C; Agarwal R; Bakris G; Charytan DM; de Zeeuw D; Heerspink HJL; Neal B; Wheeler DC; Cannon CP; Zhang H; Zinman B; Perkovic V; Levin A; Mahaffey KW; Jardine M; Brenner BM; Greene T; Jardine MJ; Meininger G; Li N; Kolesnyk I; Aizenberg D; Pecoits-Filho R; Cherney D; Obrador G; Chertow G; Chang T; Hawley C; Ji L; Wada T; Jha V; Lim SK; Lim-Abrahan MA; Santos F; Chae DW; Hwang SJ; Vazelov E; Rychlík I; Hadjadj S; Krane V; Rosivall L; De Nicola L; Dreval A; Nowicki M; Schiller A; Distiller L; Górriz JL; Kolesnyk M; David ; Wheeler C; Guerrero RAA; Albisu JP; Alvarisqueta A; Bartolacci I; Berli MA; Bordonava A; Calella P; Cantero MC; Cartasegna LR; Cercos E; Coloma GC; Colombo H; Commendatore V; Cuadrado J; Cuneo CA; Cusumano AM; Douthat WG; Dran RD; Farias E; Fernandez MF; Finkelstein H; Fragale G; Fretes JO; Garcia NH; Gastaldi A; Gelersztein E; Glenny JA; Gonzalez JP; Colaso PDCG; Goycoa C; Greloni GC; Guinsburg A; Hermida S; Juncos LI; Klyver MI; Kraft F; Krynski F; Lanchiotti PV; Leon de la Fuente RA; Marchetta N; Mele P; Nicolai S; Novoa PA; Orio SI, 2023, 'Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial', American Journal of Kidney Diseases, 82, pp. 84 - 96.e1, http://dx.doi.org/10.1053/j.ajkd.2022.12.015

Singh AK; Claggett BL; Perkovic V; Hiemstra T; Khavandi K; Lukas MA; Ranganathan P; Shannon JB; van Adelsberg J; Solomon S, 2023, '#3807 HEART FAILURE IN ASCEND-ND AND ASCEND-D', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_3807

Perkovic V; Barratt J; Radhakrishnan J; Rizk D; Trimarchi H; Khawaja Z; Leiske J; Sorensen B; King A; Jones-Burton C; Campbell K, 2023, '#4333 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', Nephrology Dialysis Transplantation, 38, http://dx.doi.org/10.1093/ndt/gfad063c_4333

Charytan DM; Mahaffey KW; Jardine MJ; Cannon CP; Neal B; Lambers Heerspink HJ; Agarwal R; Bakris GL; De Zeeuw D; Levin A; Pollock C; Zhang H; Zinman B; Rosenthal N; Perkovic V; Di Tanna GL; Yu J; Rogers K; Arnott C; Wheeler DC, 2023, 'Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering', BMJ Open Diabetes Research and Care, 11, pp. e003270, http://dx.doi.org/10.1136/bmjdrc-2022-003270

Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N, 2023, 'Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis', Nephrology Dialysis Transplantation, 38, pp. 1448 - 1458, http://dx.doi.org/10.1093/ndt/gfac289

van der Hoek S; Jongs N; Oshima M; Neuen BL; Stevens J; Perkovic V; Levin A; Mahaffey KW; Pollock C; Greene T; Wheeler DC; Jardine MJ; Heerspink HJL, 2023, 'Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial', Clinical journal of the American Society of Nephrology : CJASN, 18, pp. 748 - 758, http://dx.doi.org/10.2215/CJN.0000000000000161

Heerspink HJL; Radhakrishnan J; Alpers CE; Barratt J; Bieler S; Diva U; Inrig J; Komers R; Mercer A; Noronha IL; Rheault MN; Rote W; Rovin B; Trachtman H; Trimarchi H; Wong MG; Perkovic V; Alarmartine E; Chae DW; Del Vecchio L; Floege J; Hwang SJ; Jelakovic B; Maes B; Malecki R; Miglinas M; Nolasco FEB; Praga M; Rabindranath K; Rosenberg M; Tang SCW; Tesar V; Bose B; Gangadharan M; McDonald S; Peh C; Jahan S; Yeap C; Clayton P; Irish G; Thyagarajan N; Hollett P; Krishnasamy R; Carroll R; Jesudason S; Crail S; Coates T; Waugh J; Noble E; Mahadevan K; Campbell V; Salehi T; Lim W; Boudville N; Chakera A; Chan D; Krishnan A; Eqbal Y; Gillies A; Vilayur E; Maung Myint TM; Gray N; Cheetham M; Pollock C; Cooper B; Mather A; Roxburgh S; Shen Y; Stangenberg S; Siriwardana A; O'Lone E; Wan S; Neuen B; Tsun Kit Ha J; Kim D; Heath L; Jain A; Phua E; Li Y; Gallagher M; Jardine M; Ritchie A; Razavian M; Foote C; Wyndham R; Sen S; Endre Z; Erlich J; Fernando M; Yong K; Luxton G; Kotwal S; Roger S; Wijeratne V; Packham D; Fraser I; Vandewiele B; Laute M; Lemahieu W; Jamar S, 2023, 'Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial', The Lancet, 401, pp. 1584 - 1594, http://dx.doi.org/10.1016/S0140-6736(23)00569-X

Koshino A; Oshima M; Arnott C; Fletcher RA; Bakris GL; Jardine M; Mahaffey KW; Perkovic V; Pollock C; Heerspink HJL; Neuen BL, 2023, 'Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial', Diabetes, Obesity and Metabolism, 25, pp. 1413 - 1418, http://dx.doi.org/10.1111/dom.14978

Barratt J; Rovin B; Wong MG; Alpers CE; Bieler S; He P; Inrig J; Komers R; Heerspink HJL; Mercer A; Noronha IL; Radhakrishnan J; Rheault MN; Rote W; Trachtman H; Trimarchi H; Perkovic V, 2023, 'IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study', Kidney International Reports, 8, pp. 1043 - 1056, http://dx.doi.org/10.1016/j.ekir.2023.02.1086

Rizk DV; Rovin BH; Zhang H; Kashihara N; Maes B; Trimarchi H; Perkovic V; Meier M; Kollins D; Papachristofi O; Charney A; Barratt J, 2023, 'Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study', Kidney International Reports, 8, pp. 968 - 979, http://dx.doi.org/10.1016/j.ekir.2023.01.041

Zhang YM; Lv JC; Wong MG; Zhang H; Perkovic V, 2023, 'Glucocorticoids for IgA nephropathy—pro', Kidney International, 103, pp. 666 - 669, http://dx.doi.org/10.1016/j.kint.2023.01.018

Neuen BL; Bello AK; Levin A; Lunney M; Osman MA; Ye F; Ashuntantang GE; Bellorin-Font E; Gharbi MB; Davison S; Ghnaimat M; Harden P; Jha V; Kalantar-Zadeh K; Kerr PG; Klarenbach S; Kovesdy CP; Luyckx V; Ossareh S; Perl J; Rashid HU; Rondeau E; See EJ; Saad S; Sola L; Tchokhonelidze I; Tesar V; Tungsanga K; Kazancioglu RT; Wang AYM; Yang CW; Zemchenkov A; Zhao MH; Jager KJ; Caskey FJ; Perkovic V; Jindal KK; Okpechi IG; Tonelli M; Feehally J; Harris DC; Johnson DW, 2023, 'National health policies and strategies for addressing chronic kidney disease: Data from the International Society of Nephrology Global Kidney Health Atlas', PLOS Global Public Health, 3, http://dx.doi.org/10.1371/journal.pgph.0001467

Jain SS; Yu J; Arnott C; Neal B; Perkovic V; Neuen BL; Jardine M; Mahaffey KW, 2023, 'Treatment effect of canagliflozin for patients on therapy for heart failure: Pooled analysis of the CANVAS program and CREDENCE trial', International Journal of Cardiology, 395, http://dx.doi.org/10.1016/j.ijcard.2023.131444

Heerspink HJ; Agarwal R; Bakris GL; Cherney D; Lam CSP; Neuen BL; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen PH; Perkovic V, 2023, 'Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD', Journal of the American Society of Nephrology, 34, pp. 678 - 678, http://dx.doi.org/10.1681/asn.20233411s1678a

Tangri N; Ferguson TW; Bamforth RJ; Arnott CG; Mahaffey KW; Heerspink HJ; Perkovic V; Neuen BL, 2023, 'External Validation of a Machine Learning Model for Progression of CKD in the CREDENCE and CANVAS Trials', Journal of the American Society of Nephrology, 34, pp. 418 - 419, http://dx.doi.org/10.1681/asn.20233411s1418c

Ha J; Hiremath S; Jun M; Palmer S; Wheeler DC; Coyne DW; Perkovic V; Badve S, 2023, 'Long-Term Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in CKD: A Systematic Review and Meta-Analysis of Randomized Trials', Journal of the American Society of Nephrology, 34, pp. 367 - 367, http://dx.doi.org/10.1681/asn.20233411s1367a

Jun M; Wick J; Neuen BL; Kotwal SS; Badve S; Chalmers JP; Jardine M; Perkovic V; Gallagher MP; Ronksley PE, 2023, 'The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset', Journal of the American Society of Nephrology, 34, pp. 373 - 373, http://dx.doi.org/10.1681/asn.20233411s1373a

Jain SS; Yu J; Arnott C; Neal BC; Perkovic V; Neuen B; Jardine M; Mahaffey KW, 2023, 'TREATMENT EFFECT OF CANAGLIFLOZIN FOR PATIENTS ON THERAPY FOR HEART FAILURE: POOLED ANALYSIS OF THE CANVAS PROGRAM AND CREDENCE TRIAL', Journal of the American College of Cardiology, 81, pp. 283, http://dx.doi.org/10.1016/s0735-1097(23)00727-1

KIM D; Lv J; Hladunewich M; Jha V; Hooi LS; Monaghan H; Billot L; Zhang H; Perkovic V; Wong MG, 2023, 'WCN23-0069 EFFICACY AND SAFETY OF REDUCED-DOSE ORAL METHYLPREDNISOLONE IN IGA NEPHROPATHY: THE TESTING TRIAL', Kidney International Reports, 8, pp. S51 - S52, http://dx.doi.org/10.1016/j.ekir.2023.02.118

Barratt J; Rovin BH; Zhang H; Rizk DV; Kashihara N; Maes BD; Trimarchi H; Sprangers B; Meier M; Kollins D; Junge G; Milojevic J; Papachristofi O; Perkovic V, 2023, 'WCN23-0412 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS OVER TIME IN IgA NEPHROPATHY', Kidney International Reports, 8, pp. S271 - S272, http://dx.doi.org/10.1016/j.ekir.2023.02.612

TALBOT B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Knight J, 2023, 'WCN23-0574 THE ELLEN MEDICAL DEVICES AFFORDABLE POINT-OF-CARE PERITONEAL DIALYSIS SYSTEM - A PILOT STUDY', Kidney International Reports, 8, pp. S350 - S350, http://dx.doi.org/10.1016/j.ekir.2023.02.786

Mc Causland FR; Singh AK; Claggett BL; Carroll K; Wittes J; McMurray JJV; Perkovic V; Snapinn S; Lopes RD; Solomon SD, 2022, 'Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply', The New England journal of medicine, 387, pp. 2482 - 2485, http://dx.doi.org/10.1056/NEJMc2208182

Ridker PM; Tuttle KR; Perkovic V; Libby P; Macfadyen JG, 2022, 'Inflammation drives residual risk in chronic kidney disease: a CANTOS substudy', European Heart Journal, 43, pp. 4832 - 4844, http://dx.doi.org/10.1093/eurheartj/ehac444

Nunes JC; Yu J; Arnott C; Jardine MJ; Perkovic V; Mahaffey KW, 2022, 'Canagliflozin, mental health adverse events and diabetes: Exploratory analysis of the CREDENCE trial and CANVAS Program', Diabetes, Obesity and Metabolism, 24, pp. 2459 - 2464, http://dx.doi.org/10.1111/dom.14832

Tye SC; Jongs N; Coca SG; Sundström J; Arnott C; Neal B; Perkovic V; Mahaffey KW; Vart P; Heerspink HJL, 2022, 'Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure', Cardiovascular Diabetology, 21, pp. 194, http://dx.doi.org/10.1186/s12933-022-01619-0

Hammett C; Badve SV; Kerr PG; Tran HA; Dundon BK; Lo S; Wong A; Joseph JE; Deague J; Perkovic V, 2022, 'Oral Anticoagulant Use in Patients With Atrial Fibrillation and Chronic Kidney Disease: A Review of the Evidence With Recommendations for Australian Clinical Practice', Heart Lung and Circulation, 31, pp. 1604 - 1611, http://dx.doi.org/10.1016/j.hlc.2022.09.003

Baigent C; Emberson JR; Haynes R; Herrington WG; Judge P; Landray MJ; Mayne KJ; Ng SYA; Preiss D; Roddick AJ; Staplin N; Zhu D; Anker SD; Bhatt DL; Brueckmann M; Butler J; Cherney DZI; Green JB; Hauske SJ; Heerspink HJL; Inzucchi SE; Jardine MJ; Liu CC; Mahaffey KW; McCausland FR; McGuire DK; McMurray JJV; Neal B; Neuen BL; Packer M; Perkovic V; Sabatine MS; Solomon SD; Vaduganathan M; Wanner C; Wheeler DC; Wiviott SD; Zannad F, 2022, 'Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials', The Lancet, 400, pp. 1788 - 1801, http://dx.doi.org/10.1016/S0140-6736(22)02074-8

Kolkailah AA; Marx N; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto R; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK, 2022, 'Abstract 12404: Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', Circulation, 146, http://dx.doi.org/10.1161/circ.146.suppl_1.12404

Sarraju A; Bakris G; Cannon CP; Cherney D; Damaraju CV; Figtree GA; Gogate J; Greene T; Heerspink HJL; Januzzi JL; Neal B; Jardine MJ; Blais J; Kosiborod M; Levin A; Lingvay I; Weir MR; Perkovic V; Mahaffey KW, 2022, 'Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria', Journal of the American College of Cardiology, 80, pp. 1721 - 1731, http://dx.doi.org/10.1016/j.jacc.2022.08.772

Koshino A; Schechter M; Sen T; Vart P; Neuen BL; Neal B; Arnott C; Perkovic V; Ridker PM; Tuttle KR; Hansen MK; Heerspink HJL, 2022, 'Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS', Diabetes Care, 45, pp. 2644 - 2652, http://dx.doi.org/10.2337/dc22-0866

Smeijer JD; Koomen JV; Kohan DE; McMurray JJV; Bakris GL; Correa-Rotter R; Hou FF; Kitzman DW; Makino H; Mayer G; Nowicki M; Perkovic V; Rossing P; Tobe S; Parving HH; de Zeeuw D; Heerspink HJL, 2022, 'Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long-Term Response to Atrasentan in Patients With Diabetic Kidney Disease', Clinical Pharmacology and Therapeutics, 112, pp. 1098 - 1107, http://dx.doi.org/10.1002/cpt.2721

Back to profile page